LAG 525

Drug Profile

LAG 525

Alternative Names: Anti-LAG-3-monoclonal-antibody - Novartis Oncology; LAG525

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immutep Limited; Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Solid tumours

Most Recent Events

  • 29 Mar 2018 Immutep announces intention to launch LAG 525/IMP 701 for Solid tumours (Lung cancer) in 2025
  • 05 Mar 2018 Immutep and Novartis have patent protection for LAG 525 in USA
  • 08 Feb 2018 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03365791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top